{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:04:02Z","timestamp":1789697042694,"version":"4.0.1"},"reference-count":151,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.apsb.2024.12.024","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T16:58:54Z","timestamp":1735232334000},"page":"909-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines (Eff-iEC): A demonstration study"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3522-0424","authenticated-orcid":false,"given":"Ye","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfa","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3022-7233","authenticated-orcid":false,"given":"Shuanglin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaofang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiguo","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.12.024_bib1","unstructured":"World Health Organization. International Classification of Diseases (ICD). Available from: https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases [accessed October 23, 2024]."},{"key":"10.1016\/j.apsb.2024.12.024_bib2","unstructured":"European Academies Science Advisory Council. Traditional Chinese Medicine: A Statement by EASAC and FEAM. Available from: https:\/\/easac.eu\/publications\/details\/traditional-chinese-medicine-a-statement-by-easac-and-feam\/[accessed October 23, 2024]."},{"key":"10.1016\/j.apsb.2024.12.024_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/d41586-019-01726-1","article-title":"The World Health Organization's decision about traditional Chinese medicine could backfire","volume":"570","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.12.024_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/00005650-199711000-00001","article-title":"NIH Office of Alternative Medicine. Quantitative methods in research on complementary and alternative medicine","volume":"35","author":"Levin","year":"1997","journal-title":"Med Care"},{"key":"10.1016\/j.apsb.2024.12.024_bib5","unstructured":"World Health Organization. General guidelines for methodologies on research and evaluation of traditional medicine. Available from: https:\/\/iris.who.int\/handle\/10665\/66783 [accessed October 23, 2024]."},{"key":"10.1016\/j.apsb.2024.12.024_bib6","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMms1604593","article-title":"Assessing the gold standard\u2014lessons from the history of RCTs","volume":"374","author":"Bothwell","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib7","unstructured":"The State Council of the People\u2019s Republic of China. Guiding Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance and Innovation of Traditional Chinese Medicine. Available from: https:\/\/www.gov.cn\/zhengce\/202203\/content_3635418.htm [accessed October 23, 2024]."},{"key":"10.1016\/j.apsb.2024.12.024_bib8","first-page":"5113","article-title":"Integrated evidence chain: a new strategy and methodology for effectiveness evaluation of traditional Chinese medicines","volume":"49","author":"Xiao","year":"2024","journal-title":"China J Chin Mater Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.12.024_bib10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.12.024_bib11","doi-asserted-by":"crossref","first-page":"9671","DOI":"10.3390\/ijms24119671","article-title":"Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities","volume":"24","author":"Pei","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.12.024_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/cells11091500","article-title":"Recent advancements in antifibrotic therapies for regression of liver fibrosis","volume":"11","author":"Jangra","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2024.12.024_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.joim.2020.03.001","article-title":"Hepatology Committee of Chinese Association of Integrative Medicine, China Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition)","volume":"18","author":"Xu","year":"2020","journal-title":"J Integr Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jhep.2014.03.009","article-title":"Traditional Chinese medicine (TCM) for fibrotic liver disease: hope and hype","volume":"61","author":"Zhang","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.117514","article-title":"Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in\u00a0vivo for chronic liver disease","volume":"321","author":"Xu","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1303012","article-title":"Research progress of traditional Chinese medicine in improving hepatic fibrosis based on inhibiting pathological angiogenesis","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2019.112442","article-title":"Advances in anti hepatic fibrotic therapy with traditional Chinese medicine herbal formula","volume":"251","author":"Li","year":"2020","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib19","article-title":"Clinical efficacy and safety of eight traditional Chinese medicine combined with entecavir in the treatment of chronic hepatitis B liver fibrosis in adults: a network meta-analysis","volume":"2020","author":"Wang","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.943063","article-title":"Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis","volume":"13","author":"Dai","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1381476","article-title":"Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.117514","article-title":"Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in\u00a0vivo for chronic liver disease","volume":"321","author":"Xu","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib23","first-page":"527","article-title":"Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension","volume":"39","author":"Xu","year":"2023","journal-title":"J Clin Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib24","first-page":"2057","article-title":"Chinese consensus on clinical diagnosis and therapy of liver cirrhosis","volume":"39","author":"Lin","year":"2023","journal-title":"J Clin Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib25","first-page":"457","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2022 edition)","volume":"26","author":"You","year":"2023","journal-title":"J Pract Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib26","first-page":"461","article-title":"Guidelines for traditional Chinese medicine diagnosis and treatment of liver cirrhosis","volume":"40","author":"Wang","year":"2024","journal-title":"J Clin Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib27","first-page":"91","article-title":"Expert consensus on traditional Chinese medicine diagnosis and treatment of liver accumulation (2023)","volume":"32","author":"Lu","year":"2024","journal-title":"Chin J Integr Tradit West Med Dig"},{"key":"10.1016\/j.apsb.2024.12.024_bib28","first-page":"2543","article-title":"Guidelines for integrated traditional Chinese and Western medicine diagnosis and treatment of liver cirrhosis","volume":"39","author":"Hu","year":"2023","journal-title":"J Clin Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib29","series-title":"Chinese\u2013English textbook synopsis of prescription of the golden chamber","author":"Ruan","year":"2003"},{"issue":"2","key":"10.1016\/j.apsb.2024.12.024_bib30","first-page":"17","article-title":"Experimental study on the therapeutic effect of Biejiajian Pill on carbon tetrachloride-induced liver injury in rats","author":"Ren","year":"1995","journal-title":"Acta Chin Med"},{"issue":"3","key":"10.1016\/j.apsb.2024.12.024_bib31","first-page":"28","article-title":"Experimental study on the anti-chronic liver injury and anti-liver fibrosis effects of Dahuang Zhechong Pill","author":"Hu","year":"1995","journal-title":"Chin J Integr Tradit West Med Liver Dis"},{"issue":"5","key":"10.1016\/j.apsb.2024.12.024_bib32","first-page":"34","article-title":"Reflections on the successful registration application of compound biejia ruangan tablets","author":"Han","year":"2000","journal-title":"Chin Pharm J"},{"issue":"1","key":"10.1016\/j.apsb.2024.12.024_bib33","first-page":"16","article-title":"Treatment of hepatic cirrhosis following hepatitis with ruangan tablets: a case series of 60 patients","author":"Song","year":"1991","journal-title":"Chin J Integr Tradit West Med Liver Dis"},{"issue":"5","key":"10.1016\/j.apsb.2024.12.024_bib34","first-page":"27","article-title":"The regulatory effect of Fuzheng Huayu Formula on endocrine hormone disruption in patients with liver cirrhosis","author":"Hu","year":"1992","journal-title":"China J Tradit Chin Med Pharm"},{"key":"10.1016\/j.apsb.2024.12.024_bib35","first-page":"185","article-title":"Research progress on the anti-liver fibrosis effects of Anluo Huaxian Pill","volume":"26","author":"Nie","year":"2016","journal-title":"Chin J Integr Tradit West Med Liver Dis"},{"issue":"1","key":"10.1016\/j.apsb.2024.12.024_bib36","first-page":"27","article-title":"The protective effect of Anluo Huaxian Pill on acute and chronic liver injury","author":"Zhang","year":"1999","journal-title":"Chin J Biochem Pharm"},{"key":"10.1016\/j.apsb.2024.12.024_bib37","series-title":"Academic Annual conference of the internal medicine branch of the Chinese association of traditional Chinese medicine","article-title":"Summary of the reevaluation of clinical efficacy of Heluo Shugan Capsule in the treatment of chronic hepatitis B","author":"Wang","year":"2007"},{"issue":"2","key":"10.1016\/j.apsb.2024.12.024_bib38","first-page":"69","article-title":"Clinical study on the treatment of chronic hepatitis B with He Luo Shu Gan Capsules","author":"Huang","year":"2001","journal-title":"Chin J Integr Tradit West Med Liver Dis"},{"key":"10.1016\/j.apsb.2024.12.024_bib39","first-page":"1241","article-title":"Therapeutic effect of Biejiajian Pill on compound factor-induced fatty liver fibrosis in rats","volume":"37","author":"Zhou","year":"2014","journal-title":"J Chin Med Mater"},{"key":"10.1016\/j.apsb.2024.12.024_bib40","first-page":"3364","article-title":"Effect of Biejiajian Pill on TGF-\u03b21\/smad signal pathway in rats with liver fibrosis","volume":"44","author":"Sun","year":"2013","journal-title":"Chin Tradit Herb Drugs"},{"key":"10.1016\/j.apsb.2024.12.024_bib41","first-page":"876","article-title":"The influence of Biejiajian Pill on the expression of Wnt\/\u03b2-catenin signaling pathway-related proteins and their target genes in liver tissue of liver fibrosis model rats","volume":"59","author":"Sun","year":"2018","journal-title":"J Tradit Chin Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib42","first-page":"192","article-title":"Effect of Biejiajian Wan on hepatocyte growth factor expression in rats with immune hepatic fibrosis","volume":"18","author":"Li","year":"2012","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"10.1016\/j.apsb.2024.12.024_bib43","first-page":"161","article-title":"Effect of Biejiajian Wan on NF-\u03baB signaling pathway in rat hepatic fibrosis model induced by CCl4","volume":"24","author":"Chen","year":"2018","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"10.1016\/j.apsb.2024.12.024_bib44","first-page":"2088","article-title":"Protective effect of Biejiajian Pills on hepatitis and hepatic fibrosis induced by ConA in mice","volume":"35","author":"Liu","year":"2013","journal-title":"Chin Tradit Pat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib45","first-page":"2874","article-title":"Research on the anti-liver fibrosis mechanism of Biejiajian Pill based on network pharmacology","volume":"43","author":"Ding","year":"2021","journal-title":"Chin Tradit Pat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s11655-017-2909-7","article-title":"Balancing effect of Biejiajian oral liquid on ACE\u2013Ang II\u2013AT1R axis and ACE2\u2013Ang-(1\u20137)\u2013Mas axis in rats with CCl4-induced hepatic fibrosis","volume":"24","author":"Li","year":"2018","journal-title":"Chin J Integr Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib47","first-page":"2557","article-title":"Mechanism of Biejiajian Pills against non-alcoholic steatohepatitis based on lipidomics","volume":"49","author":"Huang","year":"2024","journal-title":"China J Chin Mater Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib48","first-page":"928","article-title":"Dahuang zhechong pills regulate ASIC1a\/VEGF pathway and alleviate hepatic fibrosis","volume":"38","author":"Cao","year":"2022","journal-title":"Chin Pharmacol Bull"},{"key":"10.1016\/j.apsb.2024.12.024_bib49","first-page":"2858","article-title":"The influence of Dahuang Zhechong Pill on the expression of BAMBI in rat liver tissue","volume":"29","author":"Liu","year":"2018","journal-title":"Lishizhen Med Mater Med Res"},{"key":"10.1016\/j.apsb.2024.12.024_bib50","first-page":"1","article-title":"Effects of Dahuangzhechong Pills on hepatic oval cell activation and expression of TIMP-1,CTGF and Notch1 in liver fibrosis rats","volume":"26","author":"Li","year":"2010","journal-title":"Pharmacol Clin Chin Mater Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib51","first-page":"2091","article-title":"The influence of Dahuang Zhechong Pill on endotoxemia in rats with liver fibrosis","volume":"28","author":"Liu","year":"2017","journal-title":"Lishizhen Med Mater Med Res"},{"key":"10.1016\/j.apsb.2024.12.024_bib52","first-page":"2475","article-title":"Protective effects of Dahuang Zhechong Pills on mice with alcohol-induced liver fibrosis","volume":"39","author":"Zhong","year":"2017","journal-title":"Chin Tradit Pat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib53","first-page":"801","article-title":"Protective effects of Dahuangzhechongwan against rat hepatic fibrosis induced by carbon tetrachloride","volume":"23","author":"Lv","year":"2012","journal-title":"Lishizhen Med Mater Med Res"},{"key":"10.1016\/j.apsb.2024.12.024_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.117402","article-title":"Dahuang zhechong pill ameliorates hepatic fibrosis by regulating gut microbiota and metabolites","volume":"321","author":"He","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib55","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/jcb.29378","article-title":"Dahuang Zhechong pill attenuates CCl4-induced rat liver fibrosis via the PI3K\u2013Akt signaling pathway","volume":"121","author":"Gong","year":"2020","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2024.12.024_bib56","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jtcm.2018.04.007","article-title":"Effect of Dahuang Zhechong pills on long non-coding RNA growth arrest specific 5 in rat models of hepatic fibrosis","volume":"38","author":"Gong","year":"2018","journal-title":"J Tradit Chin Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jep.2010.08.019","article-title":"Effects of dahuangzhechong pills on cytokines and mitogen activated protein kinase activation in rats with hepatic fibrosis","volume":"132","author":"Cai","year":"2010","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib58","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/13880209.2011.604333","article-title":"Evaluation of the liver protection and toxicity of Da-Huang-Zhe-Chong pill in rats","volume":"50","author":"Xing","year":"2012","journal-title":"Pharm Biol"},{"key":"10.1016\/j.apsb.2024.12.024_bib59","first-page":"11","article-title":"Investigation on anti-liver cancer potential and compatibility characteristics of Fufang Biejia Ruangan Pian from network perspective","volume":"26","author":"Chen","year":"2020","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"10.1016\/j.apsb.2024.12.024_bib60","first-page":"510","article-title":"Mechanism of a Chinese patent medicine in the treatment of liver fibrosis caused by infection of Clonorchis sinensis based on network pharmacology","volume":"41","author":"Li","year":"2023","journal-title":"Chin J Parasitol Parasit Dis"},{"issue":"4","key":"10.1016\/j.apsb.2024.12.024_bib61","first-page":"249","article-title":"Therapeutic efficacy study of compound Biejia Ruangan Tablets on CCl4-induced liver fibrosis model in rats","author":"Yang","year":"2003","journal-title":"Chin J Infect Control"},{"issue":"2","key":"10.1016\/j.apsb.2024.12.024_bib62","first-page":"158","article-title":"Effects of compound Biejiaruangan tablets on the expression of liver angiotension \u2161 and its receptor in rats with hepatic fibrosis","author":"Yuan","year":"2008","journal-title":"China J Tradit Chin Med Pharm"},{"issue":"7","key":"10.1016\/j.apsb.2024.12.024_bib63","first-page":"567","article-title":"Effects of FFBJRGP on collagen deposition in hepatic Disse space in alcohol induced liver fibrosis in rat","author":"Li","year":"2004","journal-title":"Med J Chin Peoples Lib Army"},{"key":"10.1016\/j.apsb.2024.12.024_bib64","first-page":"1371","article-title":"Effect of modified formula Compound Biejia Ruangan Pills on hepatic fibrosis in rats induced by CCl4 and its mechanism","volume":"49","author":"Deng","year":"2018","journal-title":"Chin Tradit Herb Drugs"},{"key":"10.1016\/j.apsb.2024.12.024_bib65","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.3748\/wjg.v19.i32.5326","article-title":"Effects of Fufang Biejia Ruangan pills on hepatic fibrosis in\u00a0vivo and in\u00a0vitro","volume":"19","author":"Yang","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2024.12.024_bib66","first-page":"104","article-title":"Effects of novel Fufang biejia ruangan tablets with sheep placenta as substitute for Hominis Placenta on CCl4-induced liver fibrosis","volume":"14","author":"Shen","year":"2022","journal-title":"Chin Herb Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib67","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.omtn.2019.12.023","article-title":"A discovery of clinically approved formula FBRP for repositioning to treat HCC by inhibiting PI3K\/AKT\/NF-\u03baB activation","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2024.12.024_bib68","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3748\/wjg.v10.i10.1487","article-title":"Influence of serum collected from rat perfused with compound Biejiaruangan drug on hepatic stellate cells","volume":"10","author":"Guo","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2024.12.024_bib69","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.4254\/wjh.v15.i9.1043","article-title":"Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet","volume":"15","author":"Dai","year":"2023","journal-title":"World J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116419","article-title":"A herbal product inhibits carbon tetrachloride-induced liver fibrosis by suppressing the epidermal growth factor receptor signaling pathway","volume":"311","author":"Qi","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib71","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/aps.2017.150","article-title":"Chinese herbal formula Fuzheng Huayu alleviates CCl4-induced liver fibrosis in rats: a transcriptomic and proteomic analysis","volume":"39","author":"Dong","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2024.12.024_bib72","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13020-023-00754-4","article-title":"Cyp4a12-mediated retinol metabolism in stellate cells is the antihepatic fibrosis mechanism of the Chinese medicine Fuzheng Huayu recipe","volume":"18","author":"Ping","year":"2023","journal-title":"Chin Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib73","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/238495","article-title":"Dynamical regulation analysis identifies molecular mechanisms of Fuzheng-Huayu Formula against hepatitis B-caused liver cirrhosis","volume":"2015","author":"Chen","year":"2015","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib74","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3892\/etm.2014.1891","article-title":"Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis","volume":"8","author":"Zhang","year":"2014","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib75","first-page":"1725","article-title":"Effect of Fuzheng Huayu capsule on serum metabolomics in rats with liver fibrosis induced by dimethylnitrosamine","volume":"41","author":"Gao","year":"2016","journal-title":"China J Chin Mater Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib76","first-page":"609","article-title":"Effect of Fuzhenghuayu compound on hepatocyte expression of Nrf2 in a mouse model of hepatic fibrosis","volume":"22","author":"Wu","year":"2014","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib77","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3468791","article-title":"Fuzheng Huayu Capsule attenuates hepatic fibrosis by inhibiting activation of hepatic stellate cells","volume":"2020","author":"Wu","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jep.2012.10.047","article-title":"Fuzheng Huayu inhibits carbon tetrachloride-induced liver fibrosis in mice through activating hepatic NK cells","volume":"145","author":"Cheng","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib79","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/1472-6882-14-449","article-title":"Fuzheng Huayu recipe alleviates hepatic fibrosis via inhibiting TNF-\u03b1 induced hepatocyte apoptosis","volume":"14","author":"Tao","year":"2014","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.117001","article-title":"Fuzheng Huayu recipe alleviates liver fibrosis via inhibiting NLRP3 inflammasome activation in macrophages","volume":"318","author":"Ping","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib81","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/935903","article-title":"Fuzheng Huayu Recipe ameliorates liver fibrosis by restoring balance between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition in hepatic stellate cells","volume":"2015","author":"Pan","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.apsb.2024.12.024_bib82","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8591892","article-title":"Fuzheng Huayu Recipe prevented and treated CCl4-induced mice liver fibrosis through regulating polarization and chemotaxis of intrahepatic macrophages via CCL2 and CX3CL1","volume":"2020","author":"Zhang","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1476-511X-11-45","article-title":"Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice","volume":"11","author":"Jia","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.apsb.2024.12.024_bib84","article-title":"Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis","volume":"9","author":"Liu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2024.12.024_bib85","first-page":"2597","article-title":"Mechanism of Fuzheng Huayu Tablets against hepatic fibrosis based on transcriptome and single-cell sequencing","volume":"49","author":"Lu","year":"2024","journal-title":"China J Chin Mater Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2019.111888","article-title":"Metabolic mechanisms of Fuzheng-Huayu formula against liver fibrosis in rats","volume":"238","author":"Hu","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib87","first-page":"404","article-title":"Modulation of IKK\u03b2\/NF-\u03baB and TGF-\u03b21\/Smad via Fuzheng Huayu recipe involves in prevention of nutritional steatohepatitis and fibrosis in mice","volume":"18","author":"Wang","year":"2015","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.apsb.2024.12.024_bib88","first-page":"197","article-title":"Prevention and therapeutic effects of Fuzheng Huayu Capsule on liver fibrosis and expression of connective tissue growth factor in rats","volume":"47","author":"Chen","year":"2016","journal-title":"J Sichuan Univ Med Sci Ed"},{"key":"10.1016\/j.apsb.2024.12.024_bib89","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/972863","article-title":"Proteomic analysis of the effect of fuzheng huayu recipe on fibrotic liver in rats","volume":"2013","author":"Xie","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib90","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3389\/fphar.2018.00525","article-title":"The active components of Fuzheng Huayu Formula and their potential mechanism of action in inhibiting the hepatic stellate cells viability\u2014a Network pharmacology and transcriptomics approach","volume":"9","author":"Xing","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib91","doi-asserted-by":"crossref","first-page":"561","DOI":"10.26502\/acbr.50170125","article-title":"Traditional Chinese medicine Fuzheng Huayu prevents development of liver fibrosis in mice","volume":"4","author":"Jiang","year":"2020","journal-title":"Arch Clin Biomed Res"},{"issue":"1","key":"10.1016\/j.apsb.2024.12.024_bib92","first-page":"9","article-title":"The inhibitory effect of Anluo Huaxian Pill on dimethylnitrosamine-induced liver fibrosis in rats","author":"Tan","year":"2010","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib93","first-page":"1","article-title":"Experimental research of Anluohuaxian Pill plus interferon-\u03b3 on schistosomal liver fibrosis in mice","volume":"31","author":"Xiao","year":"2012","journal-title":"Her Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib94","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11596-009-0111-7","article-title":"Effect of anluohuaxian tablet combined with gamma-IFN on schistosomal liver fibrosis","volume":"29","author":"Huang","year":"2009","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.apsb.2024.12.024_bib95","first-page":"267","article-title":"Effect of Anluohuaxianwan on the expression of matrix metalloproteinases and their inhibitors in rat liver with fibrosis","volume":"27","author":"Wang","year":"2019","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib96","first-page":"257","article-title":"Effects of Anluohuaxianwan on transforming growth factor-\u03b21 and related signaling pathways in rats with carbon tetrachloride-induced liver fibrosis","volume":"25","author":"Lu","year":"2017","journal-title":"Chin J Hepatol"},{"issue":"2","key":"10.1016\/j.apsb.2024.12.024_bib97","first-page":"177","article-title":"Study on the protective effect of Heluoshugan Capsule in Rats' chronic hepatic injury and its molecular mechanism","author":"Wang","year":"2002","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"2","key":"10.1016\/j.apsb.2024.12.024_bib98","first-page":"190","article-title":"Therapeutical effects and mechanisms of Heluoshugan Capsule on schistosome-infected mice with liver fibrosis","author":"Xu","year":"2006","journal-title":"Lishizhen Med Mater Med Res"},{"issue":"2","key":"10.1016\/j.apsb.2024.12.024_bib99","first-page":"129","article-title":"Study on the effect of Heluoshugan Capsule on liver fibrosis induced by schistosoma japonicum infection in mice","author":"Tong","year":"2006","journal-title":"Chin J Parasitol Parasit Dis"},{"key":"10.1016\/j.apsb.2024.12.024_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?.","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.apsb.2024.12.024_bib101","first-page":"1410","article-title":"Effect of Biejia Jian Pill on inflammatory factors and liver fibrosis indexes in patients with chronic hepatitis B complicated with cirrhosis","volume":"24","author":"Tang","year":"2018","journal-title":"J Hainan Med Univ"},{"key":"10.1016\/j.apsb.2024.12.024_bib102","first-page":"2573","article-title":"Therapeutic efficacy and impact on virological and T cell subset indicators of the combination therapy with Biejiajian Pill and recombinant human interferon \u03b1-2b in patients with chronic hepatitis B liver fibrosis","volume":"43","author":"Meng","year":"2020","journal-title":"J Chin Med Mater"},{"key":"10.1016\/j.apsb.2024.12.024_bib103","first-page":"3895","article-title":"Therapeutic efficacy of Biejiajian Pill on fibrosis after hepatic arterial embolization in elderly patients with primary liver cancer","volume":"38","author":"Du","year":"2018","journal-title":"Chin J Gerontol"},{"key":"10.1016\/j.apsb.2024.12.024_bib104","first-page":"608","article-title":"Clinical efficacy of entecavir combined with Biejiajian pills and its influence on TCM syndrome scores during the treatment of chronic hepatitis B with hepatic fibrosis and blood stasis syndrome","volume":"31","author":"Cheng","year":"2023","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11655-023-3542-2","article-title":"Efficacy of Biejiajian Pill on intestinal microbiota in patients with hepatitis B cirrhosis\/liver fibrosis: a randomized double-blind controlled trial","volume":"29","author":"Chi","year":"2023","journal-title":"Chin J Integr Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib106","first-page":"1502","article-title":"Clinical effect of Dahuang Zhechong capsules combined with entecavir in treatment of chronic hepatitis B patients with liver fibrosis","volume":"32","author":"Xie","year":"2016","journal-title":"J Clin Hepatol"},{"issue":"5","key":"10.1016\/j.apsb.2024.12.024_bib107","first-page":"808","article-title":"Clinical evaluation for effect of Rhubarb\u00a0& Eupolyphage sinensis Pills on anti-fibrosis in liver","author":"Xu","year":"2006","journal-title":"Lishizhen Med Mater Med Res"},{"key":"10.1016\/j.apsb.2024.12.024_bib108","first-page":"862","article-title":"Experimental study on effect of Dahuang Zhechong Wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B","volume":"37","author":"Zhang","year":"2012","journal-title":"China J Chin Mater Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib109","first-page":"1048","article-title":"Effect of Dahuang Zhechong pill combined with antiviral therapy on serum virus replication indexes as well as immunity and inflammation indexes in patients with chronic hepatitis B cirrhosis","volume":"23","author":"Huang","year":"2017","journal-title":"J Hainan Med Univ"},{"issue":"5","key":"10.1016\/j.apsb.2024.12.024_bib110","first-page":"1018","article-title":"Clinical study on the inhibition of liver fibrosis after hepatitis B with Dahuang Zhechong Pill","author":"Chen","year":"2005","journal-title":"Chin J Pathophysiol"},{"issue":"21","key":"10.1016\/j.apsb.2024.12.024_bib111","first-page":"1658","article-title":"Clinical efficacy of Dahuang zhechong pill on chronic hepatitis with hepatic fibrosis","author":"Li","year":"2008","journal-title":"China Pharm"},{"key":"10.1016\/j.apsb.2024.12.024_bib112","first-page":"701","article-title":"Therapeutic effect of Dahuangzhechong pills on advanced schistosomiasis","volume":"23","author":"Niu","year":"2011","journal-title":"Chin J Schistosomiasis Control"},{"key":"10.1016\/j.apsb.2024.12.024_bib113","first-page":"1894","article-title":"Dahuang Zhechong Capsules in the treatment of compensation period liver cirrhosis after hepatitis B of the syndrome of blood stasis blocking collaterals with splenomegaly: a real-world retrospective cohort study","volume":"61","author":"Mei","year":"2020","journal-title":"J Tradit Chin Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib114","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/infdis\/jiaa266","article-title":"Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"225","author":"Rong","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2024.12.024_bib115","first-page":"1962","article-title":"Effects of Compound Biejia Ruangan Tablets combined with entecavir tablets on liver function and hematoidin of patients with chronic hepatitis B blood stasis syndrome","volume":"28","author":"Wang","year":"2017","journal-title":"China Pharm"},{"key":"10.1016\/j.apsb.2024.12.024_bib116","first-page":"593","article-title":"Effect of Compound Biejiaruangan Tablets combined with entecavir therapy on liver fibrosis process and immune response state in patients with chronic hepatitis B","volume":"24","author":"Yang","year":"2018","journal-title":"J Hainan Med Univ"},{"key":"10.1016\/j.apsb.2024.12.024_bib117","first-page":"3420","article-title":"Clinical observation of Compound Biejia Ruangan Tablets combined with reduced glutathione for compensated hepatitis B liver cirrhosis","volume":"25","author":"Zhu","year":"2014","journal-title":"China Pharm"},{"key":"10.1016\/j.apsb.2024.12.024_bib118","first-page":"358","article-title":"Efficacy and safety of Fufang Biejia Ruangan tablet in patients with chronic hepatitis B complicated with hepatic fibrosis","volume":"21","author":"Chen","year":"2007","journal-title":"Chin J Exp Clin Virol"},{"key":"10.1016\/j.apsb.2024.12.024_bib119","first-page":"633","article-title":"Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study","volume":"39","author":"Zhou","year":"2019","journal-title":"J South Med Univ"},{"key":"10.1016\/j.apsb.2024.12.024_bib120","first-page":"604","article-title":"Clinical effect of combination therapy with Fufang Biejia Ruangan tablet and entecavir in patients with hepatitis B virus-related cirrhosis","volume":"22","author":"Wu","year":"2014","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib121","first-page":"358","article-title":"Efficacy and safety of Fufang Biejia Ruangan tablet in patients with chronic hepatitis B complicated with hepatic fibrosis","volume":"21","author":"Chen","year":"2007","journal-title":"Chin J Exp Clin Virol"},{"key":"10.1016\/j.apsb.2024.12.024_bib122","first-page":"775","article-title":"Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses","volume":"36","author":"Yang","year":"2016","journal-title":"J South Med Univ"},{"key":"10.1016\/j.apsb.2024.12.024_bib123","first-page":"651","article-title":"Effect of GSH combined with\u00a0compound Biejia Ruangan tablets on curative effect and hepatic fibrosis index and inflammatory factor level in treating compensated liver cirrhosis after hepatitis B analysis","volume":"21","author":"Wang","year":"2015","journal-title":"J Hainan Med Univ"},{"key":"10.1016\/j.apsb.2024.12.024_bib124","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3748\/wjg.v11.i19.2892","article-title":"Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B","volume":"11","author":"Liu","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2024.12.024_bib125","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/709305","article-title":"Therapeutic efficacy of fuzheng-huayu tablet based traditional Chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: a multicenter double-blind randomized controlled trail","volume":"2013","author":"Song","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib126","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4494099","article-title":"Efficacy and safety of a botanical Formula Fuzheng Huayu for hepatic fibrosis in patients with CHC: results of a phase 2 clinical trial","volume":"2022","author":"Hassanein","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib127","doi-asserted-by":"crossref","first-page":"277","DOI":"10.14218\/JCTH.2020.00004","article-title":"Histological outcome of Fuzheng Huayu plus entecavir combination therapy in chronic hepatitis B patients with significant liver fibrosis","volume":"8","author":"Gui","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.hbpd.2022.03.007","article-title":"Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis","volume":"21","author":"Cheng","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.apsb.2024.12.024_bib129","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11655-013-1433-7","article-title":"Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis","volume":"19","author":"Deng","year":"2013","journal-title":"Chin J Integr Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.14218\/JCTH.2023.00521","article-title":"Beneficial effects of traditional Chinese medicine Fuzheng Huayu on the occurrence of hepatocellular carcinoma in patients with compensated chronic hepatitis B cirrhosis receiving entecavir: a multicenter retrospective cohort study","volume":"12","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115599","article-title":"Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: a single arm clinical objective performance criteria trial","volume":"298","author":"Zhao","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100601","article-title":"Safety and therapeutic effects of anti-fibrotic traditional Chinese medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: study protocol for a single arm clinical objective performance criteria trial","volume":"19","author":"Chen","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.apsb.2024.12.024_bib133","first-page":"2556","article-title":"Observation of the therapeutic effect of adefovir in combination with Anluo Huaxian Wan on liver fibrosis in chronic hepatitis B","volume":"29","author":"Luo","year":"2009","journal-title":"J South Med Univ"},{"issue":"5","key":"10.1016\/j.apsb.2024.12.024_bib134","first-page":"344","article-title":"Therapeutic efficacy of adefovir dipivoxil combined with Anluo Huaxian Pill in the treatment of chronic hepatitis B","author":"Jiang","year":"2012","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib135","first-page":"1459","article-title":"Clinical exploration of 36 cases treated with adefovir dipivoxil combined with Anluo Huaxian Pill for hepatitis B liver cirrhosis","volume":"24","author":"Xu","year":"2013","journal-title":"Lishizhen Med Mater Med Res"},{"key":"10.1016\/j.apsb.2024.12.024_bib136","first-page":"2184","article-title":"Effects of adjuvant therapy with anluohuaxian capsule on serum inflammatory factors, hepatic fibrosis indexes and immune function in patients with hepatitis B cirrhosis","volume":"23","author":"Wang","year":"2017","journal-title":"J Hainan Med Univ"},{"key":"10.1016\/j.apsb.2024.12.024_bib137","first-page":"4946","article-title":"Clinical efficacy of Anluo Huaxian Pill combined with entecavir in the treatment of elderly patients with chronic hepatitis B","volume":"43","author":"Li","year":"2023","journal-title":"Chin J Gerontol"},{"key":"10.1016\/j.apsb.2024.12.024_bib138","first-page":"2512","article-title":"Clinical efficacy and mechanism of action of Anluo Huaxian Pill combined with entecavir in the treatment of hepatitis B liver cirrhosis","volume":"45","author":"Li","year":"2022","journal-title":"J Chin Med Mater"},{"key":"10.1016\/j.apsb.2024.12.024_bib139","first-page":"1157","article-title":"43 Cases of hepatic fibrosis of chronic hepatitis B treated by entecavir combined with Anluo Huaxian Pills","volume":"29","author":"Guo","year":"2010","journal-title":"Her Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib140","first-page":"1167","article-title":"Nucleoside analogues combined with Anluo Huaxian Pill in the treatment of early Hepatitis B liver cirrhosis: a case series of 49 patients","volume":"28","author":"Wang","year":"2009","journal-title":"Her Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib141","first-page":"1681","article-title":"Observation of the therapeutic efficacy of hegand in combination with Anluo Huaxian Pill for the treatment of liver fibrosis in chronic hepatitis B","volume":"24","author":"Huang","year":"2013","journal-title":"Lishizhen Med Mater Med Res"},{"key":"10.1016\/j.apsb.2024.12.024_bib142","first-page":"304","article-title":"An-Luo-Hua-Xian Pill improves the regression of liver fibrosis in chronic hepatitis B patients treated with entecavir","volume":"11","author":"Liu","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib143","first-page":"521","article-title":"Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection","volume":"27","author":"Mao","year":"2019","journal-title":"Chin J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115210","article-title":"Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: a randomized controlled trial","volume":"293","author":"Xiao","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.024_bib145","first-page":"344","article-title":"The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology","volume":"20","author":"Jiang","year":"2012","journal-title":"Chin J Hepatol"},{"issue":"2","key":"10.1016\/j.apsb.2024.12.024_bib146","first-page":"117","article-title":"Therapeutic effects of capsule Huoluoshugan on schistosomal hepatocirrhosis","author":"Sun","year":"2008","journal-title":"Chin J Schistosomiasis Control"},{"key":"10.1016\/j.apsb.2024.12.024_bib147","first-page":"1486","article-title":"Clinical effects of Heluo Shugan Tablets combined with entecavir on patients with hepatitis B virus-related active compensated liver cirrhosis","volume":"42","author":"Di","year":"2020","journal-title":"Chin Tradit Pat Med"},{"key":"10.1016\/j.apsb.2024.12.024_bib148","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jhep.2022.07.018","article-title":"Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B","volume":"77","author":"Ji","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2024.12.024_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.apsb.2024.12.024_bib150","unstructured":"China National Healthcare Security Administration, Ministry of Human Resources and Social Security of the People's Republic of China. Natl Basic Med Insur Work-related Inj Insur Maternity Insur Drug List (Version 2022), 2023, volume 3, Chinese patent medicines section, 5-21. Available from: https:\/\/www.gov.cn\/zhengce\/zhengceku\/2023-01\/18\/content_5737840.htm [accessed October 23, 2024]."},{"key":"10.1016\/j.apsb.2024.12.024_bib151","unstructured":"National Health Commission of the People\u2019s Republic of China, National Administration of Traditional Chinese Medicine. China National Essential Drug List (Version 2018), 2018. Available from: https:\/\/www.gov.cn\/zhengce\/zhengceku\/2018-12\/31\/content_5435470.htm [accessed October 23, 2024]."}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524004817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524004817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T11:46:19Z","timestamp":1741693579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524004817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":151,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2211383524004817"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.12.024","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines (Eff-iEC): A demonstration study","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}